SLDB Stock Analysis: Buy, Sell, or Hold?
SLDB - Solid Biosciences Inc. Common Stock
$6.46
-0.14 (-2.12%)
▼
5d:
-2.12%
30d:
+13.33%
90d:
+17.67%
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 05, 2026
30d
Get Alerted When SLDB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SLDB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SLDB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SLDB is currently trading at $6.46, which is considered extended relative to its 30-day fair value range of $5.34 to $6.37.
Technical Outlook: Technically, SLDB is showing sideways momentum. Immediate support is located at $5.26, while resistance sits at $6.95.
Market Sentiment: SLDB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (9th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.75 (+143.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SLDB is showing sideways momentum. Immediate support is located at $5.26, while resistance sits at $6.95.
Market Sentiment: SLDB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (9th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.75 (+143.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$5.34 -
$6.37
Company Quality Score
56/100
(HOLD)
Options IV Signal
9th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 9th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 143.8% below Wall St target ($15.75)
Fair Price Analysis
30-Day Fair Range
$5.34 -
$6.37
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.99
(15.4%)
Support & Resistance Levels
Support Level
$5.26
Resistance Level
$6.95
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
-3.21
Wall Street Target
$15.75
(+143.8%)
Revenue Growth (YoY)
-100.0%
Last updated: February 02, 2026 6:06 AM ET
Data refreshes hourly during market hours. Next update: 7:06 AM
Data refreshes hourly during market hours. Next update: 7:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SLDB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gabriel Brooks
SELL
2895 shares
2025-10-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
